Unknown

Dataset Information

0

Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors.

ABSTRACT:

SUBMITTER: Zhao W 

PROVIDER: S-EPMC8336935 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
| S-EPMC7872905 | biostudies-literature
Unknown Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
| S-EPMC5668147 | biostudies-literature
Unknown Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.
| S-EPMC8454558 | biostudies-literature
Unknown Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
| S-EPMC7218543 | biostudies-literature
Unknown The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
| S-EPMC6533774 | biostudies-literature
Unknown MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.
| S-EPMC5792548 | biostudies-literature
Unknown HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
| S-EPMC7919131 | biostudies-literature
Unknown Third generation EGFR TKIs: current data and future directions.
| S-EPMC5817792 | biostudies-literature
Unknown The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
| S-EPMC4587765 | biostudies-literature
Unknown SOX2 Epidermal Overexpression Promotes Cutaneous Wound Healing via Activation of EGFR/MEK/ERK Signaling Mediated by EGFR Ligands.
| S-EPMC6650375 | biostudies-literature